Pimobendan improves right ventricular myocardial contraction and attenuates pulmonary arterial hypertension in rats with monocrotaline-induced pulmonary arterial hypertension

Journal of Medical Ultrasonics

Volumn 41, Issue 2, 2014, Pages 173-180

  Yoshiyuki, Rieko ^a   Nakata, Telma Mary ^a   Fukayama, Toshiharu ^a   Hamabe, Lina ^a   Hsu, Huai Che ^a   Suzuki, Shuji ^a   Machida, Noboru ^a   Fukushima, Ryuji ^a   Tanaka, Ryou ^a  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

Monocrotaline; Pimobendan; Pulmonary hypertension; Rat; Right ventricular hypertrophy

Indexed keywords

MONOCROTALINE; PIMOBENDAN; UNCLASSIFIED DRUG; VETMEDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPH; ECHOCARDIOGRAPHY; HEART CATHETER; HEART CONTRACTION; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE PRESSURE; MALE; NONHUMAN; PULMONARY HYPERTENSION; RAT; SYSTOLE;

EID: 84898925443     PISSN: 13464523     EISSN: 16132254     Source Type: Journal    
DOI: 10.1007/s10396-013-0488-6     Document Type: Article

References (31)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-537.
2. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156-63.
3. Thenappan T, Shah SJ, Rich S, et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J. 2010;35:1079-87.
4. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809-15.
5. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
6. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation. 1997;95:1479-86.
7. Nakatani M, Shirotani T, Kobayashi K, et al. Effects of low dose pimobendan in patients with cor-pulmonale. J Cardiol. 1999;34:79-83.
8. Yamazaki Y, Matsumoto H, Takeda A, et al. Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema. Nihon Kyobu Shikkan Gakkai Zasshi. 1997;35:847-53.
9. Watanabe E, Shiga T, Matsuda N, et al. Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension. Cardiovasc Drugs Ther. 2003;17:375-9.
10. Sahara M, Takahashi T, Imai Y, et al. New insights in the treatment strategy for pulmonary arterial hypertension. Cardiovasc Drugs Ther. 2006;20:377-86.
11. Hashimoto G, Suzuki M, Sakai H, et al. Subvalvular aortic stenosis diagnosed by 3D transesophageal echocardiography. J Med Ultrasonics. 2013;40:141-4.
12. Ishigaki D, Okuyama H, Yuki K, et al. Serial evaluation of left ventricular contraction and relaxation in Takotsubo cardiomyopathy by 2D speckle tracking echocardiography. J Med Ultrasonics. 2012;39:265-9.
13. Tashiro H, Suda K, Tananari Y, et al. Impact of transcatheter closure of atrial septal defects on cardiac function. J Med Ultrasonics. 2012;39:147-53.
14. Honma H, Ohno T, Tokita Y, et al. Aortic valve calcification and increased stiffness of the proximal thoracic ascending aorta: association with left ventricular diastolic dysfunction and early chronic kidney disease. J Med Ultrasonics. 2011;38:179-86.
15. Ishikura F, Azakami R, Asanuma T, et al. Monocrotaline-induced pulmonary hypertension with sufficient tricuspid regurgitation in a rat model. J Med Ultrasonics. 2012;39:4.
16. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010;23:685-713 quiz 86-8.
17. Blanchard DG, Malouf PJ, Gurudevan SV, et al. Utility of right ventricular Tei index in the noninvasive evaluation of chronic thromboembolic pulmonary hypertension before and after pulmonary thromboendarterectomy. JACC Cardiovasc Imaging. 2009;2:143-9.
18. Hammarstrom E, Wranne B, Pinto FJ, et al. Tricuspid annular motion. J Am Soc Echocardiogr. 1991;4:131-9.
19. Lopez-Candales A, Rajagopalan N, Kochar M, et al. Systolic eccentricity index identifies right ventricular dysfunction in pulmonary hypertension. Int J Cardiol. 2008;129:424-6.
20. Rabe KF, Tenor H, Dent G, et al. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol. 1994;266:L536-43.
21. Chen EP, Bittner HB, Davis Jr RD, et al. Milrinone improves pulmonary hemodynamics and right ventricular function in chronic pulmonary hypertension. Ann Thorac Surg. 1997;63:814-21.
22. Hashiba E, Hirota K, Yoshioka H, et al. Milrinone attenuates serotonin-induced pulmonary hypertension and bronchoconstriction in dogs. Anesth Analg. 2000;90:790-4.
23. Mouchaers KT, Schalij I, de Boer MA, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J. 2010;36:800-7.
24. Yen CH, Tsai TH, Leu S, et al. Sildenafil improves long-term effect of endothelial progenitor cell-based treatment for monocrotaline-induced rat pulmonary arterial hypertension. Cytotherapy. 2013;15:209-23.
25. Clozel M, Hess P, Rey M, et al. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med (Maywood). 2006;231:967-73.
26. Mouchaers KT, Schalij I, Versteilen AM, et al. Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2009;297:H200-7.
27. Sawamura F, Kato M, Fujita K, et al. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. J Pharmacol Sci. 2009;111:235-43.
28. Hsiao SH, Wang WC, Yang SH, et al. Myocardial tissue Doppler-based indexes to distinguish right ventricular volume overload from right ventricular pressure overload. Am J Cardiol. 2008;101:536-41.
29. Schermuly RT, Roehl A, Weissmann N, et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2001;281:L1361-8.
30. Schermuly RT, Ghofrani HA, Enke B, et al. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med. 1999;160:1500-6.
31. Shiga T, Wakaumi M, Yajima T, et al. Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: report on two cases. Cardiovasc Drugs Ther. 2002;16:259-63.